SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer

Guy Van Hazel, V. Heinemann, N.K. Sharma, M.P.N. Findlay, J. Ricke, M. Peeters, D. Perez, B.A. Robinson, A.H. Strickland, T. Ferguson, J. Rodríguez, H. Kröning, I. Wolf, V. Ganju, E. Walpole, E. Boucher, T. Tichler, E. Shacham-Shmueli, A. Powell, P. EliadisR. Isaacs, D. Price, F. Moeslein, J. Taieb, G. Bower, V. Gebski, M. Van Buskirk, D.N. Cade, K. Thurston, P. Gibbs

    Research output: Contribution to journalArticlepeer-review

    211 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Agricultural and Biological Sciences